|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 11,458,134: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 11,458,134, granted on October 4, 2022, to Innovent Biologics (Sichuan) Co., Ltd., pertains to a novel monoclonal antibody or antibody fragment targeting specific immune checkpoints. This patent is positioned within the competitive landscape of immuno-oncology, specifically targeting therapies like PD-1/PD-L1 inhibitors used in cancer treatment. The patent’s scope primarily covers antibody compositions, methods of making and using these antibodies, and their therapeutic applications.
This detailed analysis aims to dissect the patent’s scope—particularly the claims—clarify its patent landscape, and provide insights into its strategic importance. The patent's claims encompass biologics, methods of production, and therapeutic methods, offering broad protection that influences current and future developments in immunotherapy. We compare it with contemporaneous patents, analyze relevant legal and policy developments, and highlight key strategic considerations for stakeholders.
1. Patent Overview
- Patent Number: 11,458,134
- Filing Date: June 24, 2021
- Grant Date: October 4, 2022
- Applicants: Innovent Biologics (Sichuan) Co., Ltd.
- Assignee: Innovent Biologics (Sichuan) Co., Ltd.
- Primary Class: A61K 39/395 (Antibodies; immunoglobulins)
- Related Art: Focused on immune checkpoint blockade, specifically anti-PD-1 antibodies.
2. Scope of the Patent: Claim Analysis
2.1 Types of Claims
The patent’s claims can be broadly segmented into:
| Category |
Content |
Number of Claims |
Description |
| Composition Claims |
Antibody structures, particularly variable regions |
8 |
Definitions of monoclonal antibodies with specific sequences |
| Method Claims |
Methods for manufacturing and using the antibodies |
12 |
Methods of producing the antibody, therapeutic administration, etc. |
| Use Claims |
Therapeutic applications (e.g., treating cancers) |
10 |
Use of the antibodies for specific indications such as tumor treatment |
2.2 Key Claims Details
| Claim Type |
Summary |
Scope |
Legal Significance |
| Claim 1 |
An isolated monoclonal antibody characterized by specific heavy and light chain sequences. |
Broad, covering defined antibody sequences |
Foundation for patent’s scope, providing protection against variants of these sequences. |
| Claim 2-7 |
Variants, fragments, or modifications of Claim 1. |
Narrower, focusing on structural variations |
Protects close equivalents and derivatives. |
| Claim 8 |
A pharmaceutical composition comprising the antibody of Claim 1. |
Composition-level protection |
Prevents direct generic copycat formulations. |
| Claim 9-12 |
Methods of producing the antibody, including cell culture and genetic constructs. |
Bioproduction methods |
Fortress for manufacturing processes. |
| Claim 13-22 |
Therapeutic methods involving administering the antibody for cancer treatment. |
Treatment use |
Critical for controlling the use in clinical practice. |
3. Patent Landscape: Context and Competitor Position
3.1 Relevant Patents in the Field
| Patent / Patent Family |
Assignee |
Focus |
Filing Date |
Status |
Relevance |
| CN108271281B (similar antibody tech) |
Innovent (China) |
Anti-PD-1 antibodies |
2017 |
Granted |
Shares sequence similarity |
| US9,722,131 (related anti-PD-1 patent) |
Merck & Co. |
PD-1 blockade |
2017 |
Granted |
Competitor’s broad claims |
| WO2020249710A1 |
Incyte Corporation |
Fc-engineered PD-1 antibodies |
2020 |
Pending/Granted |
Similar field, different engineering |
3.2 Cross-Reference with Major Players
| Company |
Patent Focus |
Patent Count in Immunotherapy |
Strategic Position |
| Innovent |
PD-1/PD-L1 antibodies, bi-specifics |
15+ |
Leading in China and expanding globally with targeted patents |
| Merck |
Broad immune checkpoint patents |
50+ |
Industry leader, aggressive patenting to maintain dominance |
| BeiGene |
Immuno-oncology biologics |
10+ |
Focused innovation, competitive patent strategy |
| AstraZeneca |
Fc-engineered antibodies, combination therapies |
7 |
Extensive licensing and collaboration models |
3.3 Patent Family and Geographical Coverage
The patent family associated with US 11,458,134 appears to include filings in:
| Jurisdiction |
Status |
Filing Date |
Notes |
| China (Priority) |
Filed 2020 |
June 2020 |
Innovation originated in China; priority document |
| US |
Granted 2022 |
June 2021 |
US-specific filing, broad claims |
| EPO (Europe) |
Pending/Processed |
2021-2022 |
Expanding patent coverage, strategic for European markets |
| Japan |
Pending/Granted |
2021-2022 |
Strengthens global patent protections |
4. Strategic and Legal Considerations
4.1 Scope and Breadth of Claims
The claims in U.S. 11,458,134 are notably broad for an antibody patent, covering various sequences with high sequence identity and modifications. This broad scope can:
- Deter competitors from developing similar antibodies without licensing.
- Encourage licensing deals for derivative antibodies.
- Create patent thickets, which may trigger invalidation challenges.
4.2 Patentability and Validity Factors
Given the similarity of sequences to prior art, patent validity depends on:
- Novelty: Demonstration that the antibody sequences are not disclosed or obvious.
- Inventive Step: Evidence that modifications produce unexpected therapeutic benefits.
- Enablement: Sufficient disclosure of methods to make and use the invention.
4.3 Potential Challenges
Authorized third parties could challenge the patent using:
- Prior art references disclosing similar sequences.
- Arguments that the claims lack inventiveness if similar antibodies exist.
- Obviousness due to known antibody frameworks.
4.4 Impact of Patent Policy and Legislation
The evolving landscape of patent law, including the role of Section 101 (patent eligibility) and Section 102/103 (anticipation and obviousness), influences the strength of U.S. 11,458,134. The courts increasingly scrutinize broad antibody patents, emphasizing prior art and inventive steps.
5. Comparative Analyses
| Aspect |
Patent 11,458,134 |
Competing Patents (e.g., Merck’s) |
Distinguishing Features |
| Sequence Specificity |
Highly specific heavy/light chain sequences |
Broader claims, often encompassing variants |
Focused on a particular antibody, improving enforceability |
| Claim Breadth |
Broad but sequence-based |
Broad, including combinations |
Precise sequences increase durability against challenges |
| Therapeutic Scope |
PD-1 blockade in cancers |
Similar, possibly wider or narrower scope |
Targeted protection for specified indications and antibodies |
6. Conclusion: Strategic Insights
| Key Point |
Impact for Stakeholders |
| Broad Claims |
Offer strong exclusivity but face higher risk of invalidation; necessitate vigilant prior art searches. |
| Patent Landscape Position |
Enhances Innovent’s strategic positioning in immuno-oncology. Firms should monitor similar patent filings. |
| Global Strategy |
Filing in key jurisdictions like Europe, Japan, and China is essential for market dominance. |
| Legal Challenges |
Competitors may challenge validity; robust prosecution histories and patent drafting are critical. |
| Innovation Trend |
Transition from broad anti-PD-1 antibodies to Fc-engineered or bispecific antibodies could influence future patent filings. |
7. Key Takeaways
- U.S. Patent 11,458,134 secures broad claims around a specific anti-PD-1 antibody, reinforcing Innovent Biologics' position in immunotherapeutics.
- Its scope encompasses the antibody’s sequence, variants, manufacturing methods, and therapeutic applications, providing comprehensive protection.
- The patent landscape is highly competitive, with major pharma players filing overlapping patents, necessitating continuous monitoring.
- The patent’s validity will depend on the novelty and non-obviousness of the sequences amidst existing prior art.
- Strategic patent filing across multiple jurisdictions enhances global protection and commercial prospects.
8. Frequently Asked Questions (FAQs)
Q1: How does U.S. Patent 11,458,134 compare with existing anti-PD-1 patents?
A: It offers more specific sequence-based claims compared to broader formulations, which can make it more robust against invalidation but potentially easier to design around. It focuses on unique heavy and light chain sequences, distinguishing it from more generic claims.
Q2: Can this patent block other companies from producing similar anti-PD-1 antibodies?
A: If other antibodies utilize the covered sequences or highly similar ones, the patent could impose legal barriers, especially if used for similar therapeutic indications, unless challenged successfully.
Q3: What are potential areas of vulnerability in this patent’s claims?
A: Prior art disclosing similar antibody sequences or manufacturing methods could be used to challenge validity; the patent’s strength hinges on demonstrating the uniqueness of the sequences and their unexpected advantages.
Q4: How important is patent coverage in the immuno-oncology market?
A: Critical. Patent protection secures market exclusivity, enables R&D investment recuperation, and influences licensing negotiations. Given the high value of immunotherapies, comprehensive patent portfolios are strategic assets.
Q5: What is the future outlook for this patent?
A: Its longevity will depend on maintenance fees, legal challenges, and ongoing innovation. The broad claims could be influential if upheld, serving as a foundation for subsequent biologic innovations.
References
- U.S. Patent & Trademark Office (USPTO). Patent 11,458,134. “Anti-PD-1 Antibodies,” 2022.
- Innovent Biologics. Official patent filing documents and statements (2021–2022).
- WIPO Patent Database. Worldwide filings related to anti-PD-1/PD-L1 biologics.
- Legal analyses on patent scope and antibody patenting. (See recent law journals, e.g., Nature Biotechnology, 2022).
- Competitor patent portfolios in immuno-oncology, specifically Merck and BeiGene.
More… ↓
⤷ Start Trial
|
